Radboud University Medical Centre
Nijmegen, Gelderland, 6525EZ, Netherlands
NCT Number: NCT01978132
Patients with primary hyperaldosteronism experience more cardiovascular events compared to patients with primary hypertension, independent of the blood pressure level.
In this research we hypothesize that patients with primary hyperaldosteronism are more susceptible to ischemia-reperfusion injury.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Nijmegen, Gelderland, 6525EZ, Netherlands
Patients with PHA have an increased risk of cardiovascular events, independent of blood pressure level. Also in patients suffering a myocardial infarction, circulating aldosterone levels are associated with increased mortality. In animal models of myocardial infarction, the administration of exogenous aldosterone increased infarct size, although other studies did not report this effect. In similar models, antagonists of the mineralocorticoid receptor (MR) reduced infarct size, which was completely abolished in ecto-5'-nucleotidase (CD73, the enzyme that catalyses extracellular formation of the endogenous nucleoside adenosine) and adenosine receptor knock-out mice. Therefore, we hypothesize that patients with PHA have an increased susceptibility for ischemia-reperfusion (IR)-injury due to down-regulation of the enzyme CD73. We will use the reduction in brachial flow-mediated dilation (FMD) by forearm IR as a well-validated endpoint for (endothelial) IR-injury.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
patients with primary hyperaldosteronism:
Inclusion criteria
patients with primary hypertension:
Exclusion criteria
for both arms (patients with primary hyperaldosteronism and patients with primary hypertension:
both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
Time frame: 1 day morning
primary outcome measure is the reduction in brachial artery FMD after 20 minutes of forearm ischemia and 20 minutes of reperfusion in patients with primary hyperaldosteronism (compared to patients with primary hypertension)
Time frame: one day morning (just before FMD experiment)
Blood will be drawn to determine circulating adenosine concentration and the CD73 activity on mononuclear cells
Time frame: 1 day
Just before the FMD experiment, blood will be drawn for aldosterone and renin levels. These levels will not be determined, unless the brachial artery FMD after ischemia and reperfusion is significantly reduced in patients with primary hyperaldosteronism. We will store the plasma and serum at -20 C. If applicable, the aldosterone and aldosterone-to-renin ratio will be determined to correlate the primary outcome measure to the aldosterone and ARR levels.
Time frame: 1 day
We will measure LTL in 12 patients with PHA and 12 patients with EHT to assess wether aldosterone excess increases telomere shortening in patients with PHA
Radboud University Medical Center
Other
Primary Hyperaldosteronism and Endothelial Ischemia-reperfusion Injury
Acronym: PHA-FMD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02938910
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Paris, France
View Trial DetailsNCT04251780
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Erlangen, Bavaria, Germany
View Trial DetailsNCT02934399
Acromegaly, Adrenal Gland Diseases
Athens, Greece
View Trial DetailsNCT03405025
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Cambridge, United Kingdom
View Trial Details